Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation  by Chen, Yi-Bin et al.
Biol Blood Marrow Transplant 21 (2015) 1046e1053Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgImpact of Conditioning Regimen on Outcomes for Patients
with Lymphoma Undergoing High-Dose Therapy with
Autologous Hematopoietic Cell TransplantationYi-Bin Chen 1, Andrew A. Lane 2, Brent R. Logan 3, Xiaochun Zhu 4, Görgün Akpek 5,
Mahmoud D. Aljurf 6, Andrew S. Artz 7, Christopher N. Bredeson 8, Kenneth R. Cooke 9,
Vincent T. Ho 2, Hillard M. Lazarus 10, Richard F. Olsson 11, Wael Saber 4, Philip L. McCarthy 12,
Marcelo C. Pasquini 4,*
1Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts
2Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
3Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin
4Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
5Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona
6Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
7 Section of Hematology/Oncology, University of Chicago Hospitals, Chicago, Illinois
8Department of Medicine, The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, Ontario, Canada
9Division of Pediatric Oncology, Bone Marrow Transplant Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland
10Department of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio
11Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
12Department of Medicine, Roswell Park Cancer Institute, Buffalo, New YorkArticle history:
Received 2 October 2014
Accepted 7 February 2015
Key Words:
Autologous transplantation
Lymphoma
Idiopathic pneumonia
syndromeFinancial disclosure: See Acknowl
* Correspondence and reprint r
9200 W Wisconsin Ave, CCC 5500
E-mail address: mpasquini@mc
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
There are limited data to guide the choice of high-dose therapy (HDT) regimen before autologous hematopoietic
cell transplantation (AHCT) forpatientswithHodgkin (HL) andnon-Hodgkin lymphoma (NHL).Westudied4917
patients (NHL, n¼ 3905; HL, n¼ 1012) who underwent AHCT from 1995 to 2008 using the most common HDT
platforms: carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) (n ¼ 1730); cyclophosphamide,
BCNU, and etoposide (CBV) (n ¼ 1853); busulfan and cyclophosphamide (BuCy) (n ¼ 789); and total body
irradiation (TBI)econtaining treatment (n¼ 545). CBVwas divided intoCBVhigh andCBVlowbased onBCNUdose.
We analyzed the impact of regimen on development of idiopathic pulmonary syndrome (IPS), transplantation-
relatedmortality (TRM), and progression-free and overall survival. The 1-year incidence of IPSwas 3% to 6% and
was highest in recipients of CBVhigh (hazard ratio [HR], 1.9) and TBI (HR, 2.0) compared with BEAM. One-year
TRM was 4% to 8%, respectively, and was similar between regimens. Among patients with NHL, there was a
signiﬁcant interaction between histology, HDT regimen, and outcome. Compared with BEAM, CBVlow (HR, .63)
was associated with lower mortality in follicular lymphoma (P < .001), and CBVhigh (HR, 1.44) was associated
with highermortality in diffuse large B cell lymphoma (P¼ .001). For patientswithHL, CBVhigh (HR,1.54), CBVlow
(HR, 1.53), BuCy (HR,1.77), and TBI (HR, 3.39) were associated with higher mortality compared with BEAM (P<
.001). The impact of speciﬁc AHCTregimen onpost-transplantation survival is different depending onhistology;
therefore, further studies are required to deﬁne the best regimen for speciﬁc diseases.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose therapy (HDT) with autologous hematopoietic
cell transplantation (AHCT)hasbeena standard componentof
therapy for patients with Hodgkin lymphoma (HL) [1] andedgments on page 1052
equests: Marcelo C. Pasquini, MD, MS,
, Milwaukee, WI 52336.
w.edu (M.C. Pasquini).
15.02.005
ty for Blood and Marrow Transplantation.non-Hodgkin lymphoma (NHL) [2,3] for decades. The thera-
peutic rationale of HDT with AHCT relies on enhanced cyto-
toxicity through the delivery of myeloablative doses
of chemotherapy or total body irradiation (TBI). The choice of
HDT regimen has traditionally been based on institutional
experience, and several regimens are considered standard
and routinely used for patients with all histologies of lym-
phoma [4].
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icities, based on the individual agents ormodalities used. One
example is idiopathic pneumonia syndrome (IPS), which en-
compasses noninfectious pneumonitides caused by high-
dose alkylating chemotherapy (eg, carmustine [BCNU])
or TBI and is the major pulmonary toxicity after HDT [5]. As
prompt initiation of corticosteroids can often result in clinical
improvement, early recognition of IPS is important, and the
published risk factors for IPS after AHCT are variable [6-12].
A large study of lymphoma patients undergoing AHCT in
the modern era has not been performed to deﬁne the impact
of conditioning regimens on overall outcomes or to describe
the incidence and risk factors for developing IPS and its
impact on outcomes. To this end, we undertook a large
retrospective registry study to analyze the impact of several
commonly used HDT regimens on clinical outcomes.METHODS
Data Source
The Center for International Blood and Marrow Transplant Research
(CIBMTR) includes a voluntary working group of more than 450 trans-
plantation centers worldwide that contribute detailed data on consecutive
allogeneic and autologous hematopoietic cell transplantations to a statistical
center at the Medical College of Wisconsin in Milwaukee and the National
Marrow Donor Program coordinating center in Minneapolis. Participating
centers are required to report all transplantations consecutively; patients
are followed longitudinally and compliance is monitored by on-site audits.
Computerized checks for discrepancies, physicians’ review of submitted
data, and on-site audits of participating centers ensure data quality.
Observational studies conducted by the CIBMTR are performed in compli-
ance with all applicable federal regulations pertaining to the protection of
human research participants. Protected health information used in the
performance of such research is collected and maintained in CIBMTR’s ca-
pacity as a Public Health Authority under the Health Insurance Portability
and Accountability Act privacy rule [13].Patient Selection
All adult patients (18 years) reported to the CIBMTRwho receivedAHCT
usingmarrowor peripheral blood stemcells for NHL or HL between 1995 and
2008were included in this analysis. Patientswere excluded for the following:
no post-transplantation follow-up information (n ¼ 138), BCNU given in a
regimen other than BEAM (BCNU, etoposide, cytarabine, melphalan) [14] or
CBV (cyclophosphamide, BCNU, etoposide [VP-16]) [15] (n ¼ 145), or date of
development of IPS was before the transplantation (n ¼ 23). Among re-
cipients of BEAM, caseswere excluded if the BCNUdose per body surface area
was less than 10th percentile (n¼ 228), greater than the 90th percentile (n¼
4), or if the dose was missing (n ¼ 166). Among recipients of CBV, patients
were excluded if the BCNU dose per body surface area was less than 10th
percentile (n¼137) or if the dosewasmissing (n¼241). Amongpatientswho
received non-BCNU regimens, only patients who received busulfan and
cyclophosphamide (BuCy) [16] andTBI [17]were included to theﬁnal dataset.
A total of 4917 patients were identiﬁed from 204 centers. To address the
impact of BCNU dose on outcomes, the total dose administered of BCNUwas
divided by the calculated body surface area from height and weight data
reported to the CIBMTR. According to patterns of practice, the dose distri-
bution of BCNU varied widely among recipients of CBV, clustering approxi-
mately around 300 mg/m2 (median, 296 mg/m2; range, 225 to 374 mg/m2)
and at 450 mg/m2 (median, 453 mg/m2; range, 376 to 807 mg/m2), which
were then separated into CBVlow and CBVhigh, respectively. Among recipients
of BEAM, the BCNU dose distributionwas approximately around 300 mg/m2
(median, 293 mg/m2; range, 227 to 347 mg/m2).Study Endpoints
The primary endpoint of this analysis was overall survival (OS) among
the different conditioning regimens. Secondary endpoints included IPS,
transplantation-related mortality (TRM), relapse or progression, and
progression-free survival (PFS). TRM was deﬁned as any death without
recurrent lymphoma. Relapse and progression were deﬁned as evidence of
disease recurrence censored at the date of last contact and using death in
remission as the competing hazard. PFS was deﬁned as survival without
death or relapse censored at the date of last contact.Statistical Analysis
Patient-, disease-, and transplantation-related characteristics were
described according to each conditioning regimen and compared using chi-
square tests or Kruskal-Wallis tests, as appropriate. The cumulative inci-
dence function was used for calculating IPS, TRM, relapse, or progression
outcomes accounting for competing risks. OS and PFS were analyzed by the
Kaplan-Meier method. Multivariable analysis for each outcome was per-
formed using a Cox proportional hazards model. The effect of development
of IPS on subsequent TRM, treatment failure (relapse progression or death),
and overall mortality was performed by ﬁtting a Cox model with a time-
dependent effect for prior development of IPS. Preparative regimens were
included in all models as the main effect. The proportional hazards
assumption was checked using graphical approaches or time-dependent
covariates. Stepwise model building was used to identify additional pre-
dictors besides preparative regimen, from among the following candidate
variables included: age (18 to 39, 40 to 49, 50 to 59, 60), gender, bodymass
index (<18.5, 18.5 to 25, 25 to 30, > 30, unknown), Karnofsky performance
status (KPS) (<90, 90 to 100, unknown), disease status at AHCT, number of
prior chemotherapy regimens received, year of AHCT (1995 to 1999, 2000 to
2004, 2005 to 2008), history of smoking, time from diagnosis to AHCT, prior
use of rituximab in NHL patients, and graft type (bone marrow versus pe-
ripheral blood stem cells). Interactions between preparative regimen and
other baseline characteristics were checked. Disease was tested in 2 ways:
ﬁrst, separating HL and NHL and second, separating NHL according to his-
tologies. Both ways demonstrated a signiﬁcant interaction between disease
and conditioning on several outcomes. Details of the ﬁnal model are shown
for the 4 largest disease groupings: HL, follicular lymphoma (FL), diffuse
large B cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Consid-
ering multiple comparisons across conditioning regimens, only P values
.01 were considered signiﬁcant.
RESULTS
Clinical Characteristics
Patient characteristics for each regimen are summarized
in Table 1. The cohorts differed in age, distribution of disease,
year of AHCT, KPS, prior chemotherapy, time from diagnosis
to AHCT, and prior use of rituximab in NHL patients. Re-
cipients of AHCT with BEAM were older: age  54 years,
BEAM, 53%; CBVlow, 38%; CBVhigh, 34%; BuCy, 50%; and TBI,
40%; P < .001. A lower proportion of BEAM and TBI patients
had HL: BEAM, 18%; CBVlow, 23%; CBVhigh, 37%; BuCy, 21%;
and TBI, 4%; P< .001. BEAMwas usedmore frequently in later
years of the study period: year of AHCT 2002 or later;
BEAM, 70%; CBVlow, 18%; CBVhigh, 26%; BuCy, 49%. and TBI,
19%; P< .001. For patients with NHL, prior rituximab use was
different: BEAM, 67%; CBVlow, 18%; CBVhigh, 29%; BuCy, 43%;
and TBI, 21%; P < .001. Among patients with available age-
adjusted IPI, the proportion of patients with low and low-
intermediate IPI was in the range of 82% to 88% across the
conditioning groups. The cohorts were similar in terms of
gender and median follow-up for survivors.
Idiopathic Pneumonia Syndrome
The incidence of IPS by 1 year after AHCT was as follows:
BEAM, 3% (95% conﬁdence interval [CI], 2% to 4%); CBVlow, 3%
(95% CI, 2% to 4%); CBVhigh, 6% (95% CI, 4% to 8%); BuCy, 4%
(95% CI, 2% to 5%); and TBI, 5% (95% CI, 3% to 7%). Multivariate
analysis showed that in comparison to BEAM, the risk of IPS
for each regimen was as follows: CBVlow, hazard ratio (HR),
1.07 (95% CI, .72 to 1.60); P ¼ .742; CBVhigh, HR, 1.88 (95% CI,
1.24 to 2.83); P ¼ .003; BuCy, HR, 1.25 (95% CI, .82 to 1.92);
P ¼ .30; and TBI, HR, 2.03 (95% CI, 1.30 to 3.19); P ¼ .002
(Table 2). Additional risk factors associated with the devel-
opment of IPS include the following: (1) diagnosis of HL (HR,
2.33; 95% CI, 1.68 to 3.24; P < .001), (2) female gender (HR,
1.39; 95%CI,1.05 to1.82;P¼ .019), (3) chemotherapy-resistant
disease at time of AHCT (HR,1.9; 95% CI,1.29 to 2.79; P¼ .001),
and (4) age 55 (HR,1.54; 95% CI,1.13 to 2.09; P¼ .006). In the
entire cohort, patients who developed IPS had a signiﬁcantly
higher rate of TRM (HR, 4.02; 95% CI, 3.09 to 5.24; P < .001),
Table 1
Clinical Characteristics of Patients
Characteristic BEAM CBVlow CBVhigh BuCy TBI P Value
No. of patients 1730 1249 604 789 545 e
No. of centers 126 106 92 54 68 e
Age
Median (range) 55 (18-79) 49 (18-80) 46 (18-74) 54 (18-76) 51 (19-73) <.001
Age < 54 819 (47) 775 (62) 396 (66) 392 (50) 327 (60) <.001
Gender .57
Male 1108 (64) 787 (63) 368 (61) 499 (63) 332 (60)
Female 622 (36) 462 (37) 236 (39) 290 (37) 213 (40)
KPS <.001
< 90 545 (32) 413 (33) 133 (22) 253 (32) 145 (27)
90-100 1089 (63) 809 (65) 456 (75) 501 (63) 386 (71)
Missing 96 (6) 27 (2) 15 (2) 35 (4) 14 (3)
Disease <.001
HL 316 (18) 283 (23) 224 (37) 165 (21) 24 (4)
NHL 1414 (82) 966 (77) 380 (63) 624 (79) 521 (96)
FL 254 (15) 171 (14) 60 (10) 126 (16) 152 (28)
DLBCL 735 (42) 472 (38) 190 (31) 279 (35) 161 (30)
Lymphoblastic 64 (4) 34 (3) 18 (3) 26 (3) 24 (4)
Burkitt’s/Burkitt’s like 19 (1) 29 (2) 13 (2) 9 (1) 14 (3)
MCL 162 (9) 96 (8) 47 (8) 77 (10) 91 (17)
Other 180 (10) 164 (13) 52 (9) 107 (14) 79 (14)
Disease status at AHCT <.001
PIF sensitive 304 (18) 218 (17) 109 (18) 142 (18) 90 (17)
PIF resistant 58 (3) 45 (4) 30 (5) 36 (5) 28 (5)
CR1 336 (19) 254 (20) 95 (16) 115 (15) 115 (21)
REL sensitive 422 (24) 355 (28) 166 (27) 213 (27) 112 (21)
REL resistant 104 (6) 70 (6) 45 (7) 49 (6) 35 (6)
CR2þ 430 (25) 217 (17) 104 (17) 149 (19) 70 (13)
REL/PIF untreated/unknown 22 (1) 39 (3) 28 (5) 12 (2) 13 (2)
Missing 54 (3) 51 (4) 27 (4) 73 (9) 82 (15)
Age-adjusted IPI score <.001
Low 415 (24) 398 (32) 147 (24) 172 (22) 159 (29)
Low-intermediate 386 (22) 328 (26) 171 (28) 195 (25) 150 (28)
High-intermediate 98 (6) 98 (8) 66 (11) 68 (9) 54 (10)
High 12 (<1) 8 (<1) 1 (<1) 8 (1) 4 (<1)
Undetermined 819 (47) 417 (33) 219 (36) 346 (44) 178 (33)
No. of regimens of chemotherapy received <.001
1-2 953 (55) 770 (62) 346 (57) 404 (51) 285 (52)
3 769 (44) 469 (38) 250 (42) 379 (48) 251 (46)
Use of rituximab in NHL <.001
Rituximab 949 (67) 177 (18) 110 (29) 266 (43) 109 (21)
No rituximab 465 (33) 789 (82) 270 (71) 358 (57) 412 (79)
Year of ASCT <.001
1995-1999 302 (17) 865 (69) 393 (65) 296 (37) 400 (74)
2000-2004 446 (26) 288 (23) 104 (17) 218 (27) 74 (14)
2005-2008 982 (57) 96 (7) 107 (17) 277 (35) 71 (13)
Time from dx to AHCT, median (range), mo 17 (2-383) 16 (3-259) 16 (3-362) 17 (3-282) 14 (3-272) .017
Graft type <.001
Bone marrow 15 (<1) 84 (7) 36 (6) 48 (6) 79 (14)
Peripheral blood 1715 (99) 1165 (93) 568 (94) 741 (94) 466 (86)
Dose of BCNU, median (range), mg/m2 293 (227-347) 296 (225-374) 453 (376-807) e e e
History of smoking <.001
Yes 764 (44) 491 (39) 257 (43) 347 (44) 242 (44)
No 911 (53) 658 (53) 305 (50) 401 (51) 264 (48)
Missing 55 (3) 100 (8) 42 (7) 41 (5) 39 (7)
Follow-up, median (range), mo 66 (1-193) 116 (1-217) 110 (1-216) 72 (1-194) 95 (3-206)
PIF indicates primary induction failure; CR, complete remission; REL, relapsed; IPI, International Prognostic Index; dx, diagnosis.
Data presented are n (%), unless otherwise indicated.
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shorter OS (HR, 2.50; 95% CI, 2.10 to 2.99; P < .001).TRM
There was no difference in TRM for patients with HL
compared with those with NHL, and, thus, the groups were
combined for analysis. The incidence of TRMat 1 year for each
cohortwas as follows: BEAM, 4% (95% CI, 3% to 5%); CBVlow, 7%
(95% CI, 5% to 8%); CBVhigh, 8% (95% CI, 6% to 11%); BuCy, 7%
(95% CI, 6% to 9%); and TBI, 8% (95% CI, 6% to 10%), and it was
not signiﬁcantly different after multivariate analysis.
Although choice of high-dose regimen had no effect on TRM,the following factors were associated with increased TRM:
older age, male gender, KPS < 90, chemo-resistant disease,
higher number of previously received chemotherapy regi-
mens, earlier year of AHCT, history of smoking, and use of
bone marrow as source of progenitor cells (data not shown).Relapse/Progression
The cumulative incidences of disease progression or
relapse varied according to histologies and are shown in
Table 3. Multivariate analysis of disease progression or
relapse (Table 4) demonstrated that the effect of condition-
ing on outcomewas signiﬁcant for patients withMCL and HL.
Table 2
Multivariate Analysis for IPS
Regimen Reference HR (95% CI) P Value
CBVlow BEAM 1.07 (.72-1.6) .742
CBVhigh BEAM 1.88 (1.24-2.83) .003
BuCy BEAM 1.25 (.82-1.92) .299
TBI BEAM 2.03 (1.30-3.19) .002
CBVhigh CBVlow 1.75 (1.14-2.70) .01
BuCy CBVlow 1.17 (.75-1.84) .489
TBI CBVlow 1.90 (1.19-3.04) .008
BuCy CBVhigh .67 (.42-1.06) .085
TBI CBVhigh 1.08 (.67-1.76) .746
TBI BuCy 1.62 (.99-2.65) .055
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relapse for CBVlow was .55 (95% CI, .34 to .88; P ¼ .014)
compared with BEAM. Conversely, when testing all possible
comparisons, the HR for CBVhigh and TBI were 2.28 (95% CI,
1.29 to 4.04; P< .005) and 2.28 (95% CI, 1.38 to 3.76; P¼ .001)
compared with CBVlow, respectively (Table 4). For patients
with HL, BuCy (HR, 1.52; 95% CI, 1.13 to 2.05, compared with
BEAM; P ¼ .006) and CyTBI (HR, 1.94; 95% CI, 1.09 to 3.45,
compared with BEAM; P ¼ .024) were associated with higher
rates of progression compared with BEAM, CBVlow, and
CBVhigh. Multivariate analysis also showed the following
factors to be associated with increased relapse or diseaseTable 3
Univariate Probabilities for TRM, Disease Progression or Relapse, PFS and OS acros
Outcomes BEAM (95% CI) CBVlow (95% CI) CB
HL
Progression/relapse
n 313 279 21
At 3 yr 32 (27-37) 32 (26-38) 30
PFS
n 313 279 21
At 3 yr 62 (56-67) 60 (54-66) 57
OS
n 316 283 22
At 3 yr 79 (74-83) 73 (68-79) 68
FL
Progression/relapse
n 253 171 60
At 3 yr 39 (33-46) 28 (21-35) 51
PFS
n 253 171 60
At 3 yr 52 (45-58) 67 (59-74) 41
OS
n 254 171 60
At 3 yr 73 (68-79) 81 (75-87) 55
DLBCL
Progression/relapse
n 731 465 18
At 3 yr 44 (40-47) 40 (36-45) 47
PFS
n 731 465 18
At 3 yr 47 (44-51) 47 (43-52) 39
OS
n 735 472 19
At 3 yr 58 (55-62) 55 (50-59) 43
MCL
Progression/relapse
n 162 96 47
At 3 yr 27 (21-35) 22 (14-32) 44
PFS
n 162 96 47
At 3 yr 62 (54-70) 57 (47-68) 49
OS
n 162 96 47
At 3 yr 75 (68-82) 66 (56-76) 80progression: older age, chemo-resistant disease, higher
number of prior regimens of chemotherapy, and shorter time
from diagnosis to AHCT (data not shown).
PFS and OS
For patients with NHL, probabilities of 3-year PFS were as
follows: BEAM, 51% (95% CI, 48% to 53%); CBVlow, 52% (95% CI,
49% to 55%); CBVhigh, 41% (95% CI, 36% to 46%); BuCy, 49%
(95% CI, 45% to 53%); and TBI, 50% (95% CI, 45% to 54%).
Table 3 shows 3-year PFS and OS probabilities for the 3 most
common NHL histologies: FL, DLBCL, and MCL. Multivariate
analysis for treatment failure showed no speciﬁc impact of
conditioning regimen on this outcome in FL, DLBCL, or MCL
(Table 3). Probabilities of 3-year OS were as follows: BEAM,
64% (95% CI, 61% to 66%); CBVlow, 60% (95% CI, 57% to 64%);
CBVhigh, 52% (95% CI, 47% to 57%); BuCy, 59% (95% CI, 55% to
63%); and TBI, 59% (95% CI, 55% to 63%). Multivariate analysis
for overall mortality (Table 4) demonstrated that among
patients with FL, CBVlow resulted in better outcomes
compared with BEAM (HR, .63; 95% CI, .45 to .87; P ¼ .006)
andwith CBVhigh (HR, .50; 95% CI, .33 to .78; P¼ .002). Among
patients with DLBCL, CBVhigh resulted in worse outcomes
compared with BEAM (HR, 1.44; 95% CI, 1.16 to 1.77; P¼ .001)
and CBVlow (HR, 1.38; 95% CI, 1.11 to 1.70; P ¼ .003). All
conditioning regimens resulted in similar OS among patients
with MCL. Figure 1A-C shows OS for each NHL histology.s Different HDT before AHCT for HL, FL, DLBCL, and MCL
Vhigh (95% CI) BuCy (95% CI) TBI (95% CI) P Value
9 162 23
(24-36) 41 (34-49) 57 (37-76) .026
9 162 23 .004
(50-64) 51 (43-59) 43 (24-63) .110
4 165 24 <.001
(61-74) 65 (58-73) 47 (27-68) .001
125 151
(38-63) 31 (23-39) 39 (31-47) .010
125 151
(28-54) 60 (52-69) 54 (45-62) .002
126 152
(42-68) 79 (71-86) 71 (63-78) .004
7 273 156
(40-54) 41 (35-47) 42 (35-50) .599
7 273 156
(32-46) 45 (39-52) 42 (34-50) .273
0 279 161
(36-51) 52 (46-58) 47 (40-55) .002
77 90
(30-59) 44 (33-55) 24 (16-34) .006
77 90 .611
(35-64) 47 (36-58) 62 (51-72) .165
77 91 .127
(68-90) 60 (49-71) 66 (56-76) .051
Table 4
Impact of HDT Regimen on TRM, Disease Progression or Relapse (Death or Disease Progression), and Overall Mortality by Histology
Regimen Disease Progression/Relapse P Value Treatment Failure P Value Overall Mortality P Value
HL
BEAM 1.00 .008*,y 1.00 <.001*,y 1.00 <.001*,y
CBVlow 1.12 (.85-1.47) .41 1.27 (1.01-1.61) .04 1.53 (1.16-2.02) .003
CBVhigh .95 (.71-1.28) .75 1.18 (.92-1.51) .20 1.54 (1.15-2.05) .003
BuCy 1.52 (1.13-2.05) .006y 1.51 (1.15-1.97) .003y 1.77 (1.30-2.42) <.001y
TBI 1.94 (1.09-3.46) .024 2.01 (1.21-3.34) .007y 3.38 (2.03-5.63) <.001y
CBVhigh versus CBVlow .85 (.63-1.15) .30 .92 (.73-1.18) .53 1.00 (.77-1.30) .97
BuCy versus CBVlow 1.35 (1.00-1.84) .05 1.19 (.91-1.55) .21 1.16 (.86-1.55) .32
TBI versus CBVlow 1.73 (.97-3.09) .06 1.58 (.95-2.62) .07 2.20 (1.34-3.63) .002y
BuCy versus CBVhigh 1.59 (1.15-2.21) .006y 1.28 (.97-1.70) .08 1.16 (.85-1.56) .35
TBI versus CBVhigh 2.04 (1.13-3.69) .02 1.71 (1.03-2.86) .04 2.20 (1.33-3.64) .002y
TBI versus BuCy 1.28 (.71-2.31) .42 1.33 (.79-2.25) .28 1.91 (1.13-3.20) .015
FL
BEAM 1.00 .105* 1.00 .042* 1.00 .005*,y
CBVlow .79 (.58-1.08) .23 .72 (.55-.94) .016 .63 (.45-.87) .006y
CBVhigh 1.34 (.90-2.00) .12 1.16 (.81-1.67) .42 1.24 (.83-1.86) .30
BuCy .82 (.59-1.14) .35 .77 (.58-1.03) .08 .69 (.49-.87) .035
TBI 1.03 (.76-1.41) .73 .88 (.66-1.16) .35 .93 (.68-1.28) .65
CBVhigh versus CBVlow 1.70 (1.10-2.61) .02 1.62 (1.11-2.37) .01 1.98 (1.28-3.06) .002y
BuCy versus CBVlow 1.04 (.72-1.50) .85 1.08 (.79-1.48) .63 1.10 (.74-1.62) .64
TBI versus CBVlow 1.31 (.92-1.85) .16 1.22 (.91-1.65) .19 1.48 (1.04-2.11) .03
BuCy versus CBVhigh .61 (.39-.96) .04 .67 (.45-.99) .05 .55 (.35-.97) .01y
TBI versus CBVhigh .77 (.50-1.19) .23 .76 (.51-1.11) .15 .75 (.49-1.15) .18
TBI versus BuCy 1.26 (.87-1.83) .26 1.13 (.82-1.56) .45 1.35 (.93-1.97) .11
DLBCL
BEAM 1.00 .30* 1.00 .11* 1.00 .006*,y
CBVlow 1.05 (.89-1.25) .55 1.03 (.88-1.21) .73 1.04 (.88-1.24) .63
CBVhigh 1.25 (.99-1.57) .06 1.26 (1.03-1.55) .02 1.44 (1.16-1.77) .001y
BuCy .95 (.77-1.17) .62 .99 (.83-1.19) .95 1.10 (.91-1.33) .32
TBI 1.09 (.84-1.41) .52 1.19 (.96-1.49) .12 1.29 (1.02-1.62) .03
CBVhigh versus CBVlow 1.19 (.93-1.51) .17 1.23 (1.00-1.51) .05 1.38 (1.11-1.70) .003y
BuCy versus CBVlow .90 (.72-1.13) .36 .97 (.80-1.17) .73 1.06 (.86-1.29) .59
TBI versus CBVlow 1.03 (.79-1.35) .81 1.16 (.93-1.45) .19 1.23 (.98-1.56) .07
BuCy versus CBVhigh .76 (.58-.99) .04 .79 (.62-.99) .04 .77 (.61-.97) .03
TBI versus CBVhigh .87 (.64-1.19) .38 .94 (.73-1.22) .67 .90 (.69-1.17) .42
TBI versus BuCy 1.15 (.85-1.54) .36 1.20 (.94-1.54) .14 1.17 (.91-1.50) .23
MCL
BEAM 1.00 <.001*,y 1.00 .24* 1.00 .81*
CBVlow .54 (.34-.84) .006y .80 (.58-1.12) .19 1.08 (.74-1.56) .70
CBVhigh 1.16 (.74-1.84) .51 .94 (.62-1.43) .78 .98 (.60-1.59) .94
BuCy 1.14 (.78-1.66) .50 1.02 (.73-1.42) .90 1.23 (.84-1.79) .29
TBI .52 (.33-.81) .004y .71 (.51-1.00) .05 .99 (.68-1.44) .95
CBVhigh versus CBVlow 2.17 (1.26-3.76) .005y 1.17 (.75-1.84) .48 .91 (.55-1.51) .72
BuCy versus CBVlow 2.13 (1.31-3.44) .002y 1.27 (.88-1.84) .20 1.14 (.76-1.70) .52
TBI versus CBVlow .97 (.57-1.65) .91 .89 (.62-1.27) .51 .92 (.62-1.35) .57
BuCy versus CBVhigh .98 (.60-1.60) .93 1.08 (.69-1.70) .73 1.25 (.75-2.08) .39
TBI versus CBVhigh .45 (.26-.77) .004y .75 (.48-1.19) .22 1.01 (.61-1.67) .97
TBI versus BuCy .46 (.28-.74) .001y .70 (.48-1.01) .06 .81 (.54-1.21) .29
Bold text indicates P <.05.
Data presented are HR (95% CI).
* Overall P values.
y Comparisons signiﬁcantly associated with an outcome (P < .01).
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BEAM, 62% (95% CI, 56% to 67%); CBVlow, 60% (95% CI, 54% to
66%); CBVhigh, 57% (95% CI, 50% to 64%); BuCy, 51% (95% CI,
43% to 59%); and TBI, 43% (95% CI, 24% to 63%). Multivariate
analysis demonstrated that BuCy (HR, 1.51; 95% CI, 1.15 to
1.97; P ¼ .003) and TBI (HR, 2.01; 95% CI, 1.21 to 3.34; P ¼
.007) had worse PFS compared with BEAM (Table 4). Prob-
abilities of 3-year OS were BEAM, 79% (95% CI, 74% to 83%);
CBVlow, 73% (95% CI, 68% to 79%); CBVhigh, 68% (95% CI, 61% to
74%); BuCy, 65% (95% CI, 58% to 73%); and TBI, 47% (95% CI,
27% to 68%) (Figure 1D). Multivariate analysis revealed that
patients with HL receiving BEAM had superior OS compared
with those receiving all other regimens (Table 4). Factors
associatedwith inferior OS for all patients included older age,
male gender, body mass index < 18.5, KPS < 90, chemo-
resistant disease, higher number of previous regimens ofchemotherapy received, shorter time from diagnosis to
AHCT, and use of bone marrow (data not shown).
DISCUSSION
In this large retrospective registry study of patients with
NHL and HL, we analyzed the impact of several commonly
used HDT regimens (BEAM, CBVlow, CBVhigh, BuCy, and TBI)
for AHCT on outcomes including IPS, TRM, relapse or pro-
gression, PFS, and OS. The results demonstrated clear dif-
ferential outcomes according to the conditioning regimen
utilized for patients with NHL or HL. For all patients, the
development of IPS signiﬁcantly increases the risk of death
after AHCT, and the incidence of IPS was higher in patients
receiving higher doses of BCNU and TBI-based regimens. For
patients with NHL, the outcomes further differed by speciﬁc
disease histologies, with CBVlow associated with better
Figure 1. Adjusted probability of overall survival after autologous hematopoietic cell transplantation for (A) Hodgkin lymphoma, (B) follicular lymphoma, (C) diffuse
large B cell lymphoma, and (D) mantle cell lymphoma according to conditioning regimen.
Y.-B. Chen et al. / Biol Blood Marrow Transplant 21 (2015) 1046e1053 1051survival for FL, CBVhigh being worse for DLBCL, and no dif-
ference in survival according to the conditioning regimens
studied among patients with MCL. Among patients with HL,
BEAM was associated with better survival compared with all
other regimens.
In this analysis, the development of IPS was most common
afterCBVhigh (6%)orTBI-based (5%) regimens, andpatientswho
developed IPS hadmuchworse PFS and OS. The most recently
published series investigating pulmonary toxicity after AHCT
was a retrospective study on 222 patients with lymphoma
receiving a CBVhigh regimen atMassachusetts General Hospital
and Dana-Farber Cancer Institute. Clinical factors associated
with pneumonitis included prior mediastinal radiation, total
BCNUdose1000mg,andage<54years. Importantly, 3of the
4 cases of TRM in their cohort were due to pneumonitis [12].
Although the dose of BCNUwas found to be a risk factor for IPS
in the current study, mediastinal radiation could not be vali-
datedas thisdatawasnot comprehensivelyavailable.However,
the fact that HL was associated with the diagnosis of IPS sug-
gests that the treatment of HL, which commonly includes ra-
diation, could be contributing to the increased risk. The
association of older age (rather than younger) with an
increased risk of pneumonitis may reﬂect patients with pre-
existing pulmonary disease; however, routine pulmonary
function data were also not available.
Although the choice of speciﬁc HDT regimen did not
inﬂuence the risk of TRM when adjusted for all clinical
variables, several characteristics were associated with an
increased risk of TRM, including older age, male gender, KPS
< 90%, chemo-resistant disease, higher number of previ-
ously received chemotherapy regimens, earlier year of
AHCT, history of smoking, and use of bone marrow. Most of
these variables reﬂect patient comorbidities or signiﬁcant
changes in supportive care and patient selection over time,
and have previously been shown to be associated with TRM
after AHCT.
Interestingly, the impact of HDT regimen on the risk of
disease relapse or progression differed in NHL versus HL. For
example, patients with MCL who received CBVlow or TBIexperienced lower rates of disease progression. For patients
with HL, those who received either BuCy or TBI-based regi-
mens had a signiﬁcantly increased risk of relapse compared
with patients who received BEAM or either CBV regimen. Of
greater interest, these effects translated into better OS out-
comes in some subsets. For example, in FL the use of CBVlow
was associated with better survival, but there was no effect
on disease progression or TRM. One explanation is that there
are few TRM events after AHCT, which makes it challenging
to observe differences within each disease histology. Pro-
gression after AHCT is a much more common event, and
therefore, if a conditioning regimen results in inferior disease
control and is associated with higher toxicity, this may
translate into higher overall mortality.
These ﬁndings are noteworthy given that many practi-
tioners are of the opinion that all standard HDT regimens
yield similar outcomes across all lymphoma types as long as
myeloablative doses are employed. This belief is supported
by many single-arm series and the study by Vose et al. from
the Blood and Marrow Transplant Clinical Trials Network
[18] describing outcomes of different regimens, all of which
show comparable results but are impossible to directly
compare with each another. Appropriately, in recent years,
most centers have moved away from using TBI-based regi-
mens given the long-term sequelae of TBI [19-21], particu-
larly the increased risk for secondary malignancies [22].
Moreover, retrospective studies have suggested improved
efﬁcacy with chemotherapy-alone regimens compared with
TBI-based regimens [23-25].
Recent studies support our ﬁnding of the superiority of
BEAM for HL. The Nebraska Lymphoma Study Group per-
formed a retrospective analysis on 225 patients with HL who
received AHCT between 1984 and 2007. Importantly, they
only included patients who were alive after 2 years, and they
compared outcomes of BEAM versus CBV. At 10 years, PFS
was 79% for BEAM and 59% for CBV (P ¼ .01), and OS was 84%
for BEAM versus 66% for CBV (P ¼ .02) [26]. More recently,
investigators used a matched control analysis to compare
outcomes of a cohort of 184 lymphoma patients enrolled on a
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busulfan, cyclophosphamide, and etoposide (BuCyE) to
controls who received BEAM from the CIBMTR database.
Toxicity and TRM appeared to be comparable between the
groups. Outcomes for patients with NHL were equivalent
between BuCyE and BEAM; however, for patients with HL,
patients receiving BuCyE had a signiﬁcantly higher rate of
progression and much shorter PFS [27]. Recently, in-
vestigators have incorporated newer agents into traditional
high-dose regimens. Visani et al. conducted a phase I/II study
on 43 patients using bendamustine, etoposide, cytarabine,
and melphalan (BeEAM) conditioning for AHCT for relapsed/
refractory lymphoma and showed an impressive complete
remission rate of 81% at a median follow-up of 18 months
[28]. Vose et al. have conducted several trials combining 131-
Iodine tositumomab with BEAM for AHCT, but no clear
advantage was observed in the phase III trial [18,29,30].
Other trials have studied gemcitabine, busulfan, and
melphalan [31]; busulfan, melphalan, and thiotepa [32]; and
the additions of (90)Y-ibritumomab tiuxetan [33] or borte-
zomib [34], respectively, to BEAM conditioning. Clearly,
prospective randomized trials will determine if incorpora-
tion of these newer agents into HDT regimens has signiﬁcant
value, but based on our results, the selection of the control
needs to take into account the differences in outcomes based
on histologies.
The limitations of our analysis are those inherent to any
large registry study. For example, the patients who received
BEAM were predominantly treated in a more recent era, and
thus, any improvements observed could have been partly
due to improved supportive care, patient selection, or
salvage therapy. These variables may not be well adjusted for
in our multivariate model, although year of transplantation
and source of stem cells were included and were not
signiﬁcantly associated with outcomes. In addition, the reg-
imens were given heterogeneously, according to individual
center standards, which includes the order and rate of
chemotherapy administration, use of systemic corticoste-
roids as antiemetics, and institution-speciﬁc supportive care,
all of which could inﬂuence toxicities, such as the develop-
ment of IPS. The method by which the diagnosis of IPS was
made was based on the individual center’s deﬁnition of IPS
and the lack of pulmonary infection. Given the large number
of patients treated at many centers over many years, indi-
vidual cases could not be validated centrally. Furthermore,
we were unable to analyze if pre-existing pulmonary
dysfunction (as deﬁned by standard pulmonary function
tests) inﬂuenced the development of IPS given the incom-
pleteness of available data. The study compared the most
common high-dose regimens used in lymphoma; however,
in some subgroups, for example recipients of TBI for HL, the
numbers are too small. This needs to take into consideration
when interpreting the results.
In summary, we have conducted the largest study to date
on lymphoma patients undergoing AHCT, comparing out-
comes of 5 commonly used HDT regimens. In this large
cohort, IPS was a signiﬁcant complication of all regimens, but
more commonly observed after CBVhigh or TBI-based regi-
mens. The development of IPS had a profoundly negative
effect on OS. In terms of OS, patients with FL appeared to do
best with CBVlow, whereas patients with HL appeared to do
best with BEAM. Regimens with higher doses of BCNU were
associated with higher incidences of IPS, and in DLBCL
resulted in highermortality. In conclusion, there is variability
in toxicity and disease outcomes among speciﬁc AHCTregimens. Further analyses in speciﬁc lymphoma subtypes
are important to understand the best regimen that maxi-
mizes disease control with lower toxicities.ACKNOWLEDGMENTS
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